Research ArticleOriginal Research

Primary Care Physician Perspectives about Antipsychotics and Other Medications for Symptoms of Dementia

J. William Kerns, Jonathan D. Winter, Katherine M. Winter, Terry Boyd and Rebecca S. Etz
The Journal of the American Board of Family Medicine January 2018, 31 (1) 9-21; DOI: https://doi.org/10.3122/jabfm.2018.01.170230

References

  1. 1.↵
    1. Lyketsos CG,
    2. Lopez O,
    3. Jones B,
    4. Fitzpatrick AL,
    5. Breitner J,
    6. DeKosky S
    . Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002;288:1475–83.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Galvin JE,
    2. Sadowsky CH,
    3. Nincds A
    . Practical guidelines for the recognition and diagnosis of dementia. J Am Board Fam Med 2012;25:367–82.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Tampi RR,
    2. Williamson D,
    3. Muralee S,
    4. et al
    . Behavioral and psychological symptoms of dementia: part I - epidemiology, neurobiology, heritability, and evaluation. Clin Geriatr 2011;19:41–6.
    OpenUrl
  4. 4.↵
    1. Buckley T,
    2. Fauth EB,
    3. Morrison A,
    4. et al
    . Predictors of quality of life ratings for persons with dementia simultaneously reported by patients and their caregivers: the Cache County (Utah) Study. Int Psychogeriatr 2012;24:1094–102.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Afram B,
    2. Stephan A,
    3. Verbeek H,
    4. et al
    ; RightTimePlaceCare Consortium. Reasons for institutionalization of people with dementia: informal caregiver reports from 8 European countries. J Am Med Dir Assoc 2014;15:108–16.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Gitlin LN,
    2. Kales HC,
    3. Lyketsos CG
    . Nonpharmacologic management of behavioral symptoms in dementia. JAMA 2012;308:2020–9.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. O'Neil ME,
    2. Freeman M,
    3. Christensen V,
    4. Telerant R,
    5. Addleman A,
    6. Kansagara D
    . A systematic evidence review of non-pharmacological interventions for behavioral symptoms of dementia. Washington (DC): Department of Veterans Affairs (US); 2011.
  8. 8.↵
    1. Tampi RR,
    2. Williamson D,
    3. Mittal V,
    4. McEnerney N,
    5. Thomas J,
    6. Cash M
    . Behavioral and psychological symptoms of dementia: part II–treatment. Clin Geriatr 2011;19:31–2, 34–40.
    OpenUrl
  9. 9.↵
    1. Fitzsimmons S,
    2. Barba B,
    3. Stump M
    . Diversional and physical nonpharmacological interventions for behavioral and psychological symptoms of dementia. J Gerontol Nur 2015;41:8–17.
    OpenUrl
  10. 10.↵
    1. Sloane PD,
    2. Hoeffer B,
    3. Mitchell CM,
    4. et al
    . Effect of person-centered showering and the towel bath on bathing-associated aggression, agitation, and discomfort in nursing home residents with dementia: a randomized, controlled trial. J Am Geriatr Soc 2004;52:1795–804.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Corbett A,
    2. Smith J,
    3. Creese B,
    4. Ballard C
    . Treatment of behavioral and psychological symptoms of Alzheimer's disease. Curr Treat Options Neurol 2012;14:113–25.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Ballard CG,
    2. Gauthier S,
    3. Cummings JL,
    4. et al
    . Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol 2009;5:245–55.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Cooke ML,
    2. Moyle W,
    3. Shum DH,
    4. Harrison SD,
    5. Murfield JE
    . A randomized controlled trial exploring the effect of music on agitated behaviours and anxiety in older people with dementia. Aging Ment Health 2010;14:905–16.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Yang MH,
    2. Lin LC,
    3. Wu SC,
    4. Chiu JH,
    5. Wang PN,
    6. Lin JG
    . Comparison of the efficacy of aroma-acupressure and aromatherapy for the treatment of dementia-associated agitation. BMC Complement Altern Med 2015;15:93.
    OpenUrl
  15. 15.↵
    1. Gerdner LA,
    2. Hart LK,
    3. Zimmerman MB
    . Craniosacral still point technique: exploring its effects in individuals with dementia. J Gerontol Nur 2008;34:36–45.
    OpenUrl
  16. 16.↵
    1. Kerns JW,
    2. Winter JD,
    3. Winter KM,
    4. Kerns CC,
    5. Etz RS
    . Caregiver perspectives about using antipsychotics and other medications for symptoms of dementia. Gerontologist 2017;00:1–11. doi:10.1093/geront/gnx042. Advance Access publication April 11, 2017.
    OpenUrlCrossRef
  17. 17.↵
    1. Berry SD,
    2. Placide SG,
    3. Mostofsky E,
    4. et al
    . Antipsychotic and benzodiazepine drug changes affect acute falls risk differently in the nursing home. J Gerontol A Biol Sci Med Sci 2016;71:273–8.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Sink KM,
    2. Holden KF,
    3. Yaffe K
    . Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293:596–608.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Clerici F,
    2. Vanacore N,
    3. Elia A,
    4. et al
    ; Memantine Lombardy Study Group. Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study. Neurol Sci 2012;33:23–31.
    OpenUrlPubMed
  20. 20.↵
    1. Miller LJ
    . The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease. Consult Pharm 2007;22:754–62.
    OpenUrlPubMed
  21. 21.↵
    1. Seitz DP,
    2. Adunuri N,
    3. Gill SS,
    4. Gruneir A,
    5. Herrmann N,
    6. Rochon P
    . Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011;(2):CD008191.
  22. 22.↵
    1. Porsteinsson AP,
    2. Drye LT,
    3. Pollock BG,
    4. et al
    ; CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 2014;311:682–91.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Konovalov S,
    2. Muralee S,
    3. Tampi RR
    . Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int Psychogeriatr 2008;20:293–308.
    OpenUrlPubMed
  24. 24.↵
    1. Sommer OH,
    2. Aga O,
    3. Cvancarova M,
    4. Olsen IC,
    5. Selbaek G,
    6. Engedal K
    . Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. Dement Geriatr Cogn Disord 2009;27:155–63.
    OpenUrlPubMed
  25. 25.↵
    1. Porsteinsson AP,
    2. Tariot PN,
    3. Erb R,
    4. et al
    . Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001;9:58–66.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Olin JT,
    2. Fox LS,
    3. Pawluczyk S,
    4. Taggart NA,
    5. Schneider LS
    . A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry 2001;9:400–5.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Ng B,
    2. Camacho A,
    3. Bardwell W,
    4. Sewell DD
    . Lamotrigine for agitation in older patients with dementia. Int Psychogeriatr 2009;21:207–8.
    OpenUrlPubMed
  28. 28.↵
    1. Buskova J,
    2. Busek P,
    3. Nevsimalova S
    . Gabapentin in the treatment of dementia-associated nocturnal agitation. Med Sci Monit 2011;17:CS149–51.
    OpenUrlPubMed
  29. 29.↵
    1. De Leon OA
    . Treatment of psychotic symptoms with lamotrigine in Alzheimer disease. J Clin Psychopharmacol 2004;24:232–3.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Devanand DP,
    2. Pelton GH,
    3. D'Antonio K,
    4. et al
    . Low-dose lithium treatment for agitation and psychosis in alzheimer disease and frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord 2017;31:73–5.
    OpenUrl
  31. 31.↵
    1. Devarajan S,
    2. Dursun SM
    . Aggression in dementia with lamotrigine treatment. Am J Psychiatry 2000;157:1178.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Forester B,
    2. Vanelli M,
    3. Hyde J,
    4. et al
    . Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication. Am J Geriatr Pharmacother 2007;5:209–17.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Herrmann N,
    2. Lanctot KL,
    3. Rothenburg LS,
    4. Eryavec G
    . A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dement Geriatr Cogn Disord 2007;23:116–9.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Lonergan E,
    2. Luxenberg J
    . Valproate preparations for agitation in dementia. Cochrane Database Syst Rev 2009;(3):CD003945.
  35. 35.↵
    1. Roane DM,
    2. Feinberg TE,
    3. Meckler L,
    4. Miner CR,
    5. Scicutella A,
    6. Rosenthal RN
    . Treatment of dementia-associated agitation with gabapentin. J Neuropsychiatry Clin Neurosci 2000;12:40–3.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. Sival RC,
    2. Haffmans PM,
    3. Jansen PA,
    4. Duursma SA,
    5. Eikelenboom P
    . Sodium valproate in the treatment of aggressive behavior in patients with dementia–a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 2002;17:579–85.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Olivieri-Mui BL,
    2. Devlin JW,
    3. Ochoa A,
    4. Schenck D,
    5. Briesacher B
    . Perceptions vs. evidence: therapeutic substitutes for antipsychotics in patients with dementia in long-term care. Aging Ment Health 2017;1 [Epub ahead of print].
  38. 38.↵
    Depakote [package insert]. North Chicago, IL: AbbVie Inc. Accessed November 2017 at https://www.depakote.com/hcp/important-safety-information.
  39. 39.↵
    Tegretol box warning. East Hanover (NJ): Novartis Pharmaceuticals Corp.; 2007. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018927s039lbl.pdf. Accessed March 29, 2017.
  40. 40.↵
    1. Lee PE,
    2. Gill SS,
    3. Freedman M,
    4. Bronskill SE,
    5. Hillmer MP,
    6. Rochon PA
    . Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004;329:75.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Maher AR,
    2. Maglione M,
    3. Bagley S,
    4. et al
    . Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011;306:1359–69.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Schneider LS,
    2. Dagerman KS,
    3. Insel P
    . Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934–43.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    U.S. Food and Drug Administration. Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. April 11, 2005. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm053171.htm. Accessed August 26, 2016.
  44. 44.↵
    Information for healthcare professionals: conventional antipyschotics. June 16, 2008. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm. Accessed November 20, 2017.
  45. 45.↵
    Press releases: Senators Blumenthal, Kohl, Grassley seek to protect the elderly and taxpayers from abusive overprescribing of antipsychotics. September 21, 2012. Available from: https://www.blumenthal.senate.gov/newsroom/press/release/senators-blumenthal-kohl-grassley-seek-to-protect-the-elderly-and-taxpayers-from-abusive-overprescribing-of-antipsychotics. Accessed September 6, 2016.
  46. 46.↵
    Informed consent for psychotropic medications for nursing home residents. Wisconsin Department of Health Services, Madison Wisconsin. Last revised December 11, 2015. Available from: http://www.dhs.wisconsin.gov/rl_dsl/NHs/psychtroMed.htm. Accessed June 8, 2017.
  47. 47.↵
    H.R.3545 - Omnibus Budget Reconciliation Act of 1987. 100th Congress. Available from: https://www.congress.gov/bill/100th-congress/house-bill/3545. Accessed June 12, 2017.
  48. 48.↵
    Centers for Medicare & Medicaid Services. CMS announces national partnership to improve dementia care in nursing homes [press release]. May 30, 2012. Available from: https://www.cms.gov/Newsroom/MediaReleaseDatabase/Press-Releases/2012-Press-Releases-Items/2012–05-30.html. Accessed August 26, 2016.
  49. 49.↵
    Center for Clinical Standards and Quality/Survey & Certification Group. Interim report on the CMS national partnership to improve dementia care in nursing homes: Q4 2011–Q1 2014. Baltimore: Department of Health & Human Services, Centers for Medicare & Medicaid Services. April 11, 2014. Available from: https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/Survey-and-Cert-Letter-14–19.pdf. Accessed August 26, 2016.
  50. 50.↵
    Center for Clinical Standards and Quality/Survey & Certification Group. Interim report on the CMS national partnership to improve dementia care in nursing homes. Baltimore: Department of Health & Human Services, Centers for Medicare & Medicaid Services. June 3, 2016. Available from: https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/Survey-and-Cert-Letter-16–28.pdf. Accessed March 1, 2017.
  51. 51.↵
    American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616–31.
    OpenUrlCrossRefPubMed
  52. 52.↵
    Best practice guideline for accommodating and managing behavioural and psychological symptoms of dementia in residential care: a person-centered interdisciplinary approach. Province of British Columbia, Canada: Ministry of Health. October 25, 2012. Available from: http://www.health.gov.bc.ca/library/publications/year/2012/bpsd-guideline.pdf. Accessed September 6, 2016.
  53. 53.↵
    Challenging behaviors. Chicago: Alzheimer's Association; 2011. Available from: https://www.alz.org/national/documents/statements_antipsychotics.pdf. Accessed September 6, 2016.
  54. 54.↵
    National Institute for Health and Care Excellence. Dementia: Supporting people with dementia and their careers in health and social care. Clinical guideline CG42. Published November 2006; updated September 2016. Available from: https://www.nice.org.uk/guidance/CG42/chapter/1-Guidance#interventions-for-noncognitive-symptoms-and-behaviour-that-challenges-in-people-with-dementia. Accessed September 6, 2016.
  55. 55.↵
    1. Reus VI,
    2. Fochtmann LJ,
    3. Eyler AE,
    4. et al
    . The APA practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry 2016;173:543–6.
    OpenUrlCrossRefPubMed
  56. 56.↵
    Treatments for behavior. Chicago: Alzheimer's Association; 2017. Available from: http://www.alz.org/alzheimers_disease_treatments_for_behavior.asp. Accessed June 12, 2017.
  57. 57.↵
    1. Leeman J,
    2. Sandelowski M
    . Practice-based evidence and qualitative inquiry. J Nurs Scholarsh 2012;44:171–9.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Crabtree BF,
    2. Miller WL
    . Doing qualitative research. 2nd ed. Thousand Oaks (CA): Sage Publications; 1999.
  59. 59.↵
    1. Sandelowski M
    . Sample size in qualitative research. Res Nurs Health 1995;18:179–83.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    1. Bradley EH,
    2. Curry LA,
    3. Devers KJ
    . Qualitative data analysis for health services research: developing taxonomy, themes, and theory. Health Serv Res 2007;42:1758–72.
    OpenUrlCrossRefPubMedWeb of Science
  61. 61.↵
    1. Carey JW,
    2. Morgan M,
    3. Oxtoby MJ
    . Intercoder agreement in analysis of responses to open-ended interview questions: examples from tuberculosis research. Cult Anthropol Methods 1996;8:1–5.
    OpenUrl
  62. 62.↵
    1. Ryan GW,
    2. Bernard HR
    . Techniques to identify themes. Field Methods 2003;15:85–109.
    OpenUrlCrossRef
  63. 63.↵
    1. Gitlin LN,
    2. Winter L,
    3. Dennis MP,
    4. Hodgson N,
    5. Hauck WW
    . A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers: the COPE randomized trial. JAMA 2010;304:983–91.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    1. Cornege-Blokland E,
    2. Kleijer BC,
    3. Hertogh CM,
    4. van Marum RJ
    . Reasons to prescribe antipsychotics for the behavioral symptoms of dementia: a survey in Dutch nursing homes among physicians, nurses, and family caregivers. J Am Med Dir Assoc 2012;13:80.e1–6.
    OpenUrlPubMed
  65. 65.↵
    1. Woolf SH,
    2. Krist AH,
    3. Johnson RE,
    4. Stenborg PS
    . Unwanted control: how patients in the primary care setting decide about screening for prostate cancer. Patient Educ Couns 2005;56:116–24.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords